PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jkneurosocJournal of Korean Neurosurgical SocietyJournalInstructions for AuthorsOn-line Submission
 
J Korean Neurosurg Soc. 2010 August; 48(2): 157–161.
Published online 2010 August 31. doi:  10.3340/jkns.2010.48.2.157
PMCID: PMC2941860

Primary Spinal Cord Melanoma

Min Soo Kim, M.D.,1 Do Heum Yoon, M.D.,2 and Dong Ah Shin, M.D.corresponding author1

Abstract

Primary central nervous system (CNS) melanoma is a rare condition that accounts for only 1% of all melanomas. A 34-year-old Korean female presented with a two-month history of progressive weakness in both legs. Spinal magnetic resonance image (MRI) revealed a spinal cord tumor at the level of T4, which was hyperintense on T1-weighted imaging and hypointense on T2-weighted imaging. The intradural and extramedullary tumor was completely resected and diagnosed as melanoma. There were no metastatic lesions. At three years after surgery, the patient is still alive, with no evidence of tumor recurrence. We present the details of this case along with a comprehensive review of spinal cord melanoma.

Keywords: Melanoma, Spinal neoplasm, Surgical treatment, Prognosis

INTRODUCTION

Although metastatic melanoma is the third most common cause of central nervous system (CNS) metastases, primary CNS melanoma is rare and accounts for only 1% of all melanomas4,10). Primary spinal cord melanoma is even rarer, but has been reported previously4,10). We found 38 relevant articles on primary spinal cord melanoma using Medline search and found 3 Korean articles reported domestically. However, none of these reports studied a large number of patients. The largest series addressed only 5 cases11). Therefore, the precise incidence, treatment, and prognosis are still unclear. The purpose of this study was to present a comprehensive review of all relevant articles along with our case.

CASE REPORT

A 34-year-old Korean woman was admitted for truncal numbness and progressive weakness in both legs. She had suffered from numbness in her right leg in the past and had been medicated for twelve months prior to admission. Her past medical history was unremarkable. She underwent a lumbar magnetic resonance image (MRI) scan at another hospital six months after symptoms began. The MRI scan revealed no abnormality, but her symptoms became progressively worse. She developed weakness in both legs and truncal numbness below the T4 level two months before admission. Thoracic MRI scan revealed a solid intramedullary lesion at the T4 level (Fig. 1), which showed slightly increased signal intensity on T1-weighted imaging, hypointense on T2-weighted imaging, and homogenously enhancing following gadolinium injection. Neurological examination revealed grade 3/5 strength in the right leg and grade 4/5 strength in the left leg associated with hypesthesia below the T4 level. Deep tendon reflexes were normal and sphincter function was intact. Absence of a primary origin outside the spinal cord was confirmed after dermatological, ophthalmological, and gastrointestinal examinations and positron emission tomography scanning. The patient underwent T4 laminectomy. After dural incision, a dark-pigmented mass was noted on the surface of the spinal cord. The mass was dissected along a cleavage plane and was completely resected. The mass was black-colored, well-demarcated, and soft. Pathological examination revealed epitheloid tumor cell proliferation with dense deposition of melanin granules (Fig. 2). Nuclear pleomorphism and mitoses were also noted. The patient's postoperative course was uneventful, and no adjuvant therapy was performed. She was followed in our outpatient clinic on a frequent basis, and she improved to walking status without assistance. At three years after surgery, the patient was free of clinical signs of metastasis, and postoperative MRI showed no recurrence (Fig. 3).

Fig. 1
Sagittal magnetic resonance images (MRI) of thoracic area. A : T1-weighted MRI shows the spinal cord tumor at the level of T4, which has high signal intensity relative to that of the cord and combined syrinx. B : T2-weighted MRI shows homogenous signal ...
Fig. 2
Microscopic finding. A : Photomicrograph shows atypical, bizarre cells with large pleomorphic nuclei, macronucleoli, and mitoses (H & E, ×1250). B : Immunohistochemical stains for human melanoma black-45 (HMB-45) reveals cytoplasmic reactivity ...
Fig. 3
Magnetic resonance images (MRI) obtained 3 years after surgery showed no residual enhancing lesion in Gadolilium-enhanced T1-weighted sagittal (A) and T2-weighed sagittal (B) view. Syrinx cavity was disappeared.

DISCUSSION

Incidence

Primary melanoma of the CNS is rare, accounting for only 1% of all melanoma cases4,10). The incidence of primary spinal cord melanoma cannot be found in the literature, but it would be extremely rare. All published surgical cases are summarized in Table 1. The characteristics of cases described in unavailable articles are described through reference to other articles that reviewed the relevant cases. Sex ratio was 1 : 1 (male : female). The mean age was 54 years and ranged from 20 to 80 years. Thoracic cases were most common (42.3%) followed by cervical cases (34.6%), thoracolumbar cases (11.5%), cervicothoracic cases (7.7%), and lumbar cases (3.8%). Exophytosis was present in 50% of reviewed cases. It appears that primary spinal cord melanoma usually arises from the leptomeninges, regardless of its precise cellular origin. It is believed that primary melanoma of the spinal cord arises either from leptomeningeal melanoblasts or from neuroectodermal congenital rests15,22). Leptomeningeal melanoblasts penetrate the spinal cord with the vascular bundles5). Epidermal melanoblasts reach the leptomeninges when the neural crest is formed.

Table 1
Summary of primary intramedullary spinal cord melanoma. Unobtainable data are left as blank

Diagnosis

The clinical symptoms are non-specific10). Progressive weakness seen in the present case is the most common symptom. The mean symptom duration in previous cases was 15 months and ranged from 0.3 to 96 months. At the present time, MRI is the best method for diagnosing spinal cord tumors. However, distinction of tumor type based on MRI findings remains difficult. The differential diagnosis includes melanocytoma, intermediategrade melanocytic tumor, and melanotic schwannoma3,4). Melanomas characteristically show hyperintesity on T1-weighted images, hypointensity on T2-weighted images, and homogeneous enhancement on T1-contrast-enhanced images4). The paramagnetic properties of melanin or intratumoral hemorrhage probably lead to these findings4). However, these are also observable in other melanocytic tumors. Thus, the ultimate diagnosis can only be made on the basis of histopathological examination. Melanocytoma is immunoreactive for HMB-45 and S-100 protein. In addition, the most specific feature of melanocytoma is the formation of tight nests surrounded by well differentiated melonocytes with cytoplasm rich in melanin3). Such disposition is absent in melanomas and in intermediate grade-lesions. Intermediate-grade melanocytic tumors are differentiated from melanomas in the degree of hypercellularity, cytologic atypia, and mitotic activity3). Melanotic schwannomas show strong pericellular immunoreactivity for collagen type IV, whereas melanocytomas typically show perilobular and perivascular staining3). If the diagnosis of spinal cord melanoma is made, differentiation of primary melanoma from a metastatic lesion should be undertaken. Whereas life expectancy is less than one year in patients with metastatic melanoma to the CNS, a number of patients with primary CNS melanoma experience long-term survival and even cure3,11,17,19,20). This is the main reason why distinction between primary and metastatic melanoma is important. Primary spinal cord melanoma is diagnosed when the following criteria, proposed by Hayward, are met : 1) there is no malignant melanoma outside the central nervous system, and 2) the lesion is confirmed pathologically6). The present case satisfied these criteria.

Treatment

Surgical resection has traditionally been the standard treatment for primary spinal cord melanoma3,4,10). In the literature, operation was performed in 26 patients. Complete resection was achieved in 12 cases (46.2%), and subtotal resection was achieved in 14 cases (53.8%). The efficacy of radiotherapy and chemotherapy is still controversial5,7,14). Radiotherapy was performed in 11 of 26 patients. The mean radiation dose was 47 Gy and ranged from 30 to 60 Gy. While radiation therapy has been performed by many authors, the radiosensitivity of malignant melanoma is questionable5). Stereotactic radiosurgery may be an alternative treatment for this lesion2,18), but it needs further studies to define its role. Two patients underwent intravenous chemotherapy. One patient was treated with dacarbazine (DTIC)22), and the other was treated with vincrisine, bleomycin, and cisplatin1). They both lived at least one year. However, data on the response to chemotherapy were not available in these two case reports. Biotherapy-including interferon-α, interferon-γ, interleukin-2, and lymphokine-activated killer (LAK) cells--has been attempted in other melanomas and can be tried in primary CNS melanoma21). At the present time there is no data concerning the effect of radiotherapy or chemotherapy on survival. Fifteen patients received no adjuvant therapy. Among them, seven patients survived more than one year, and three patients survived more than two years. However, long-term follow-up data were not available for them.

Prognosis

Although the survival rate for CNS melanoma has not yet been determined, the overall prognosis seems to be better than that of cutaneous melanoma, which is usually fatal within six months because of systemic involvement3,11,17,19,20). The clinical course of CNS melanoma is unpredictable. Larson et al.11) reported an average life expectancy of approximately seven years after surgery with radiotherapy. The mean survival duration was 28.8 months and ranged from 3 to 156 months. Seventeen patients died during follow-up, and the mean duration to death was 40 months and ranged from 8 to 156 months (Table 1). The characteristics of the CNS might contribute to the indolent nature of this disease. In contrast to cutaneous melanoma, lymphatic spread would be difficult because there are no lymphatics in the spinal cord. The blood-brain barrier of the spinal cord might also prevent hematogenous spread. The variable clinical course of primary spinal cord melanoma resembles primary uveal melanoma3). While the natural history and prognostic parameters for primary uveal melanoma are well delineated21), those for primary spinal cord melanoma are not. The rarity of primary spinal cord melanoma might be one reason for this. The known prognostic parameters for primary uveal melanoma are tumor diameter, patient age and gender, histological features, and tumor location21). Older patients of male sex have worse prognosis, as do patients with larger tumors of the choroid and ciliary body. In 1931, Callender first classified uveal melanomas into the following groups according to the shape and differentiation status of the cells : spindle A cells (fine chromatin and no distinct nucleoli), spindle B cells (plumper nuclei, more nucleoli and coarser chromatin), and epithelioid cells (pleomorphic)3). McLean reported that the best prognosis was seen in pure spindle cell tumors, regardless of type. A worse prognosis was seen in mixed tumors, and the worst prognosis was seen in epithelioid cell tumors13). Brat reported that CNS melanocytic neoplasms probably share these features3). According to this classification system, our case was in the spindle A cell classification, which has the best prognosis. Retrospective review of histopathological features was impossible, because histopathological photomicrographs were not available in many reports.

Follow-up

Because primary spinal cord melanoma has an unpredictable clinical course, annual follow-up visits and MRI follow-up are recommended for an extended period22).

CONCLUSION

Primary spinal cord melanoma is distinct from cutaneous melanoma, and its clinical course is unpredictable. Long-term study in a large series is necessary to delineate the natural history, prognostic parameters, and treatment modalities for primary spinal cord melanoma. The present case shows that complete resection alone, without any adjuvant therapy, may result in a favorable outcome for primary spinal cord melanoma of pure spindle cell type.

References

1. Bae BC, Song GS, Cha SH, Park DJ, Choi CH, Lee YW. Primary spinal malignant melanoma in the cervical spinal cord : Case report. J Korean Neurosurg Soc. 1996;25:1929–1934.
2. Benzil DL, Saboori M, Mogilner AY, Rocchio R, Moorthy CR. Safety and efficacy of stereotactic radiosurgery for tumors of the spine. J Neurosurg. 2004;101:413–418. [PubMed]
3. Brat DJ, Giannini C, Scheithauer BW, Burger PC. Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol. 1999;23:745–754. [PubMed]
4. Farrokh D, Fransen P, Faverly D. Mr findings of a primary intramedullary malignant melanoma : case report and literature review. Am J Neuroradiol. 2001;22:1864–1866. [PubMed]
5. François P, Lioret E, Jan M. Primary spinal melanoma : case report. Br J Neurosurg. 1998;12:179–182. [PubMed]
6. Hayward RD. Malignant melanoma and the central nervous system. A guide for classification based on the clinical findings. J Neurol Neurosurg Psychiatry. 1976;39:526–530. [PMC free article] [PubMed]
7. Hirano A, Carton CA. Primary malignant melanoma of the spinal cord. J Neurosurg. 1960;17:935–944. [PubMed]
8. Jung HH, Kim SH, Chung SS, Lee HJ. Malignant melanoma in the spinal cord : report of a case. J Korean Neurosurg Soc. 1974;3:59–62.
9. Kiel FW, Starr LB, Hansen JL. Primary melanoma of the spinal cord. J Neurosurg. 1961;18:616–629. [PubMed]
10. Kounin GK, Romansky KV, Traykov LD, Shotekov PM, Stoilova DZ. Primary spinal melanoma with bilateral papilledema. Clin Neurol Neurosurg. 2005;107:525–527. [PubMed]
11. Larson TC, 3rd, Houser OW, Onofrio BM, Piepgras DG. Primary spinal melanoma. J Neurosurg. 1987;66:47–49. [PubMed]
12. Magni C, Yapo P, Mocaer J, Renjard L, Sonier CB, Cottier JP, et al. [Primary intramedullary melanoma. Apropos of a case.] J Neuroradiol. 1996;23:41–45. [PubMed]
13. McLean IW, Saraiva VS, Burnier MN., Jr Pathological and prognostic features of uveal melanomas. Can J Ophthalmol. 2004;39:343–350. [PubMed]
14. Narayan RK, Rosner MJ, Povlishock JT, Girevendulis A, Becker DP. Primary dural melanoma : a clinical and morphological study. Neurosurgery. 1981;9:710–717. [PubMed]
15. Ozden B, Barlas O, Hacihanefioğlu U. Primary dural melanomas : report of two cases and review of the literature. Neurosurgery. 1984;15:104–107. [PubMed]
16. Pappenheim E, Bhattacharji SK. Primary melanoma of the central nervous system. Clinical-pathological report of a case, with survey and discussion of the literature. Arch Neurol. 1962;7:101–113. [PubMed]
17. Salame K, Merimsky O, Yosipov J, Reider-Groswasser I, Chaitchik S, Ouaknine GE. Primary intramedullary spinal melanoma : diagnostic and treatment problems. J Neurooncol. 1998;36:79–83. [PubMed]
18. Shin DA, Huh R, Chung SS, Rock J, Ryu S. Stereotactic spine radiosurgery for intradural and intramedullary metastasis. Neurosurg Focus. 2009;27:E10. [PubMed]
19. Skarli SO, Wolf AL, Kristt DA, Numaguchi Y. Melanoma arising in a cervical spinal nerve root : report of a case with a benign course and malignant features. Neurosurgery. 1994;34:533–537. discussion 637. [PubMed]
20. Vaquero J, de Prado F, Pedrosa M. Primary intraparenchymatous spinal cord melanoma. Spinal Cord. 1998;36:363–365. [PubMed]
21. Wöll E, Bedikian A, Legha SS. Uveal melanoma : natural history and treatment options for metastatic disease. Melanoma Res. 1999;9:575–581. [PubMed]
22. Yamasaki T, Kikuchi H, Yamashita J, Asato R, Fujita M. Primary spinal intramedullary malignant melanoma : case report. Neurosurgery. 1989;25:117–121. [PubMed]
23. Yoo KH, Rim CS, Lee KC, Chu JW. A case of primary melanoma in the spinal cord. J Korean Neurosurg Soc. 1987;16:523–528.

Articles from Journal of Korean Neurosurgical Society are provided here courtesy of The Korean Neurosurgical Society